Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC

NIPIRESCUE evaluates nivolumab and ipilimumab in patients with MSI/dMMR mCRC resistant to anti-PD1 monotherapy and previously treated with fluoropyrimidine, oxaliplatine, irinotecan, and anti- vascular endothelial growth factor (VEGF) or anti- epidermal growth factor receptor (EGFR) therapy.

Trial Details

NCT ID
NCT05310643
Phase
PHASE2
Sponsor
GERCOR - Multidisciplinary Oncology Cooperative Group
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • Nivolumab
  • Ipilimumab
Locations (sample)
  • Besançon, France|47.24878,6.01815
  • Bordeaux, France|44.84124,-0.58046
  • Lille, France|50.63391,3.05512
  • Limoges, France|45.83362,1.24759
  • Lyon, France|45.74906,4.84789

Key Eligibility Criteria

  • Signed and dated patient informed consent form and willingness to comply with all study procedures and availability for the study duration,
  • Age ≥ 18 years,
  • Eastern Cooperative Oncology Group performance status (ECOG PS) of 0, 1, and 2,
  • Histologically confirmed colorectal adenocarcinoma,

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →